Breast and Gynaecological Cancers and Medical Cannabis

This module focuses on Breast, endometrial and ovarian cancers (BEOC), which are among the most prevalent cancers affecting individuals assigned female at birth (IAFABP). Learners will explore the categories, pathophysiology, risk factors, symptoms, and treatment options for these cancers, noting that early symptoms, particularly for ovarian and endometrial cancers, can often go unnoticed, leading to a poorer prognosis. While common treatments can be effective, they frequently come with significant side effects that impact daily life and overall well-being.

By the end of this module, learners will be able to explain the pathophysiology and symptomatology of BEO cancers, identify treatment options and their adverse effects, and discuss the therapeutic potential of medical cannabis for alleviating treatment-related side effects, including chemotherapy-induced nausea and vomiting (CINV).

Additionally, the module will cover important considerations for selecting appropriate medical cannabis products and outline general conditions related to prescribing these treatments.

Preview this module by watching the video above.

Estimated Duration: 1 hours

Access Duration: 12 months from date of purchase

Upon completion of this module, you’ll be able to:

• Explain BEOC pathogenesis and pathophysiology
• Identify benefits and drawbacks of conventional interventions for BEOC
• Discuss medical cannabis’ therapeutic potential for treating BEOC symptoms and treatment-related side effects
• Identify considerations for selecting a medical cannabis product to treat symptoms of BEO cancers